Montelukast API Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Montelukast API Market Trends and Insights

Rising Asthma and Allergic Rhinitis Treatment Demand

The Montelukast API market draws its core volume from respiratory and allergy treatment needs that persist across healthcare systems, even when local prescribing practices differ. The World Health Organization reported that asthma affected 363 million people in 2025. This patient base supports ongoing demand for an oral leukotriene receptor antagonist in generic medicine portfolios, where treatment decisions also reflect affordability and local access to specialist care. Allergic rhinitis can occur alongside asthma, which can add to treatment demand rather than simply shift use between indications. The Montelukast API market benefits where diagnosis, patient awareness, and primary care access improve in lower-income settings, because these changes can convert previously untreated respiratory symptoms into regular medicine use. The resulting demand is most durable when suppliers can support both established asthma treatment and allergy-related formulations with consistent quality, dependable documentation, and commercially practical order sizes.

Generic-First Payer Economics

Generic substitution and step-therapy practices support recurring procurement of montelukast in North America and Europe, where payers often look for affordable treatment options before approving more complex therapies. These practices can keep a low-cost oral treatment in formularies before a patient moves to more costly therapies, which gives procurement planning a degree of continuity. The Montelukast API market therefore retains a base of repeat purchasing even when prescribers weigh competing clinical options and guideline recommendations. Lower finished-dose prices can limit revenue per unit, but they can also support broad access, recurring prescription use, and sustained order volumes for established products. Producers with suitable regulatory documentation can be favored in longer supply arrangements for regulated destinations, because changing an API source can create a significant qualification burden for the finished-dose customer. This pattern makes reliability, quality records, market-specific filings, and the ability to respond to audits as important as price in supplier decisions.

Pediatric Chewable and Granule Demand

Pediatric formulations create a differentiated area of demand within the Montelukast API market because patient age, administration needs, and caregiver preferences influence the format that a formulator must develop. Chewable tablets are used for children aged 2 to 5 years at 4 mg and for those aged 6 to 14 years at 5 mg, while 4.00 mg oral granules can be used from 6 months of age. Granule and liquid formulations require careful work on solubility, taste masking, bioavailability, and physical stability before they can be supplied at scale. The American Academy of Allergy, Asthma, and Immunology reported that climate-related changes can increase allergen exposure and affect children in particular. Hospital pharmacies and pediatric purchasing groups can use longer supply contracts than retail generic channels, which can provide more visibility for suppliers that meet their quality requirements. This gives technically capable producers a reason to develop product forms with well-documented particle characteristics, moisture controls, and formulation support for customers serving younger patients.

Extended Allergy Seasons and Perennial Rhinitis

Longer pollen seasons can increase the period during which allergic rhinitis requires management, moving demand beyond the narrow seasonal procurement pattern that some suppliers have historically expected. A review reported that 16 of 30 eligible studies found longer pollen seasons and higher pollen concentrations associated with climate change. The same review reported projected North American pollen-emission growth of 16% to 40% by the end of the century and a potential extension of 19 days in the pollen season. A study covering 2002 to 2024 found earlier and longer seasons for Alnus and Cupressaceae in Central European cities, adding regional evidence that seasonal exposures are changing.^{[1]Source: Wiley, “How Is Climate Change Affecting Seasonal Allergies?,” Wiley Newsroom, newsroom.wiley.com.} The Montelukast API market may consequently see demand distributed more evenly across the year rather than concentrated in a short seasonal period, particularly for products intended for allergy management. Continuous-batch production is better aligned with that procurement pattern than seasonal manufacturing campaigns, because customers can require steadier inventory availability and less reliance on short-term replenishment.

Safety, Pricing, and Compliance Pressures

The FDA requires a Boxed Warning for montelukast because of serious mental health side effects, including suicidal thoughts and actions. For allergic rhinitis, the FDA advises reserving the medicine for patients who have not responded to, or cannot tolerate, other allergy medicines. A Swedish cohort study published in 2025 covering 74,291 children and adolescents found no statistically significant difference in neuropsychiatric adverse events between montelukast and LABA users, with a hazard ratio of 0.99 and a 95.00% confidence interval of 0.84 to 1.16. The warning can reduce new starts for allergic rhinitis while having less effect on established asthma treatment, creating a different impact across application areas. Mature generic competition continues to pressure prices across the Montelukast API market, particularly when multiple qualified sources can bid for the same tablet program. At the same time, nitrosamine assessments, testing, and synthetic-route documentation can raise qualification costs and limit the suppliers able to serve regulated channels, making compliance expense a practical restraint for smaller producers.

Shift Toward Inhaled Corticosteroid-Based Treatment Pathways

The 2025 GINA strategy report identifies inhaled corticosteroid-containing treatment as the preferred controller approach and states that leukotriene receptor antagonists are less effective than daily inhaled corticosteroids, especially for preventing exacerbations. This guidance can limit the role of montelukast in treatment sequences where managed-care systems closely follow guideline hierarchies and measure clinical outcomes against controller-treatment standards. The UK regulator also advised clinicians in 2024 to consider the risk of neuropsychiatric reactions when prescribing montelukast. Inhaler regimens can offer stronger clinical control for many patients, but device use, regular technique, and adherence can be barriers that do not arise in the same way with oral treatment. Oral dosing still has a role where inhaler technique is difficult, caregivers prefer an oral option, or step-therapy protocols retain montelukast before treatment escalation. The Montelukast API market is therefore constrained by clinical preference without losing its established place in several patient pathways and formulation portfolios.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Crystalline Form Holds the Established Manufacturing Base

Montelukast Sodium Crystalline held 64.70% of the Montelukast API market share by product type in 2025. Its position reflects extensive manufacturing validation and established quality agreements with film-coated tablet producers. The form offers physical stability and predictable compressibility during high-volume tableting. These attributes can reduce process variability for generic finished-dose manufacturers. Storage and handling practices are also familiar to many existing formulation facilities. The crystalline form, therefore, remains closely linked to adult and adolescent tablet demand.

Montelukast Sodium Amorphous is forecast to grow at an 11.40% CAGR from 2026 to 2031. Its higher apparent solubility and faster dissolution support oral granules and oral solution matrices. This makes the form relevant to products intended for younger patients. Shilpa Pharma Lifesciences received a Certificate of Suitability CEP 2024-125 for montelukast sodium in amorphous form. Stability expectations for amorphous materials place a greater emphasis on documentation and technical controls. These requirements can favor suppliers with the capacity to maintain robust quality packages.

By Dosage-Form Compatibility: Film-Coated Tablets Lead While Granules Expand

Film-Coated Tablets represented 56.40% of the Montelukast API market share by dosage-form compatibility in 2025. The format serves substantial adult and adolescent asthma treatment volumes. It also remains simple to distribute through broad generic supply chains. Long-running supply agreements and formulary continuity support stable procurement for this format. Chewable Tablets are important for children aged 2 to 14 years. Oral Solutions, Suspensions, and Syrups serve patients who require liquid formulations and provide a smaller but stable demand base.

Oral Granules are forecast to grow at a 13.20% CAGR through 2031. Granules can be mixed with breast milk, infant formula, or soft food for very young children. This feature can reduce administration barriers for patients from 6 months of age. The Montelukast API market size for granule-related sourcing is supported by pediatric care requirements and rising allergen exposure. The 2025 AAAAI report linked climate change with changes in aerobiology, rhinitis, and allergy management needs. Granule formulators need an API with documented particle-size and moisture-sensitivity profiles. This link supports demand for amorphous API as the granule format expands.

By Application: Asthma Retains the Largest Base and Allergic Rhinitis Grows Faster

Asthma accounted for 58.70% of the Montelukast API market share by application in 2025. It remains the primary and most established indication for montelukast. The large global asthma burden gives the application a persistent treatment base. Existing regimens can continue even where clinical guidance favors inhaled alternatives. Exercise-Induced Bronchoconstriction is a smaller indication with an FDA-approved use for montelukast. Urticaria and other respiratory and allergic applications add smaller volumes through specialist prescribing in some markets.

Allergic Rhinitis is forecast to grow at a 13.80% CAGR from 2026 to 2031. The application grows faster than the overall Montelukast API market despite prescribing limits in the United States. The difference reflects demand across regions with rising exposure to urban pollution and aeroallergens. Earlier and longer pollen seasons can also expand the treated patient pool.^{[2]Source: D. Molnár et al., “Rising Allergenic Risk in Cities: A Progressive Pollen Calendar Analysis in Response to Climate Change in Central Europe,” Regional Environmental Change, link.springer.com} The FDA warning creates caution for new allergic rhinitis use, especially where alternative therapies are available. Demand across several geographies prevents a single regulatory approach from determining all application-level procurement.

Geography Analysis

North America held 40.50% of the Montelukast API market share in 2025. The region has a developed generic formulation system and extensive managed-care use of step-therapy protocols. These conditions support predictable procurement for qualified API suppliers. The FDA Boxed Warning introduces limits on allergic rhinitis initiation, but established asthma use remains important. Longer pollen seasons can support allergy-related prescribing over a greater part of the year. Health Canada updated its nitrosamine guidance in August 2025, adding compliance considerations for suppliers to Canadian import channels^{[3]Source: Health Canada, “Nitrosamine Impurities in Medications: Overview,” Government of Canada, canada.ca}.

Europe remains a technically demanding destination for the Montelukast API market. The European Medicines Agency and CMDh published joint guidance on nitrosamine impurity risk management in July 2025. The guidance includes nitrosamine drug substance-related impurities and strengthens the focus on mitigation and control. Suppliers serving the region need clear quality and regulatory documentation. Earlier and extended seasons for specific pollen types in Central European cities support a wider allergic rhinitis treatment period. Safety advice in the United Kingdom can temper prescribing while not removing the oral treatment option.

Asia-Pacific is forecast to expand at a 14.50% CAGR between 2026 and 2031, the highest regional rate in the Montelukast API market. India is an important source of API supply for regulated export markets. Regional demand also comes from China, India, Japan, South Korea, and Australia. Pediatric formats and allergy treatment needs provide a route for broader use across the region. South America and Middle East and Africa begin from smaller procurement bases. Brazil uses ANVISA-regulated pathways, while Gulf Cooperation Council tenders can increase the emphasis on qualified API supply. The geographic mix rewards suppliers able to meet different regulatory and formulation requirements without weakening quality controls.